Repare Therapeutics to Participate in Two Upcoming Investor Conferences

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two investor conferences in February and March. Details for the fireside chats are as follows:

Guggenheim Oncology Conference
Date: Thursday, February 9, 2023
Time: 3:20 p.m. Eastern Time
Location: New York, NY

Cowen 43rd Annual Health Care Conference
Date: Wednesday, March 8, 2023
Time: 9:50 a.m. Eastern Time
Location: Boston, MA

A live webcast of the fireside chats can be accessed in the Investor section of the Company’s website at https://ir.reparerx.com/news-and-events/events. A replay of the webcasts will be archived on the Company’s website for at least 30 days.

About Repare Therapeutics, Inc.

Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes RP-6306, a PKMYT1 inhibitor currently in Phase 1 clinical development; camonsertib (also known as RP-3500), a potential leading ATR inhibitor currently in Phase 1/2 clinical development partnered with Roche; RP-2119, a Polθ inhibitor program in ongoing IND-enabling studies; as well as several additional, undisclosed preclinical programs. For more information, please visit reparerx.com.

SNIPRx® is a registered trademark of Repare Therapeutics Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230202005021/en/

Repare Contact:

Robin Garner
Executive Director and Head of Investor Relations
Repare Therapeutics Inc.
[email protected]

Investors:

Matthew DeYoung
Argot Partners
[email protected]

Media:

David Rosen
Argot Partners
[email protected]
212-600-1902

Source: Repare Therapeutics Inc.

You May Also Be Interested In

• Gopuff Expands Private Label Assortment and Introduces First-Ever Seasonal Product Lineup
• Powell Investment Advisors Welcomes Michael Baiter to the Firm
• American Fusion Inc. (OTC: AMFN) Receives FINRA Clearance of Form 211 Under SEC Rule 15c2-11